SMO ClinPlus Co., Ltd. Class A

SMO ClinPlus Co., Ltd. Class A

SSZSE:301257
32.48
CNY
-0.78
(-2.35%)
0.37EPS
114.22P/E
3.37BMarket Cap
May 04Next Earn

Total Valuation

CNY

As of September 30, 2026, SMO ClinPlus Co., Ltd. Class A carries a market capitalization of 3.37B, placing it among publicly traded companies globally. Its enterprise value stands at 2.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.37B
Enterprise Value2.83B

Important Dates

SMO ClinPlus Co., Ltd. Class A's next confirmed earnings release is scheduled for May 4, 2027.

Earnings Date5/4/2027

Share Statistics

As of September 30, 2026, SMO ClinPlus Co., Ltd. Class A has 79.00M shares outstanding.

Shares Outstanding79.00M

Valuation Ratios

As of September 30, 2026, SMO ClinPlus Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 114.22. The price-to-sales ratio is 4.13, and the price-to-book ratio stands at 2.66.

PE Ratio114.22
PS Ratio4.13
PB Ratio2.66
P/TBV Ratio2.66

Enterprise Valuation

As of September 30, 2026, SMO ClinPlus Co., Ltd. Class A trades at an EV/EBITDA multiple of 64.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.45 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 64.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.83B versus a market cap of 3.37B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.45
EV / EBITDA64.72
EV / EBIT64.72

Financial Position

As of September 30, 2026, SMO ClinPlus Co., Ltd. Class A maintains a current ratio of 4.86, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.17, indicating conservative leverage, while an interest coverage ratio of 220.96 demonstrates strong ability to service its debt obligations.

Current Ratio4.86
Quick Ratio2.22
Debt / Equity0.17
Debt / EBITDA0.05
Interest Coverage220.96

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, SMO ClinPlus Co., Ltd. Class A posted a return on equity (ROE) of 2.38, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.43 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.99, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.39, useful for judging operating efficiency across full business cycles. The company generates approximately 187,491.33 in revenue per employee across its workforce of 4,372.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)2.38
Return on Assets (ROA)1.99
Return on Invested Capital (ROIC)2.43
Return on Capital Employed (ROCE)2.39
Revenue Per Employee187,491.33
Employee Count4,372.00

Taxes

CNY

Over the twelve months ended September 30, 2026, SMO ClinPlus Co., Ltd. Class A recorded 12.71M in income tax expense. That works out to an effective tax rate of 30.00, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 42.36M, leaving 29.65M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax12.71M
Effective Tax Rate30.00

Stock Price Statistics

CNY

As of the close on November 17, 2026, SMO ClinPlus Co., Ltd. Class A's stock has declined approximately 28.82% over the past 52 weeks. The 50-day moving average sits at 36.52, while the 200-day moving average is 49.14.

52-Week Price Change-28.82%
50-Day Moving Average36.52
200-Day Moving Average49.14

Income Statement

CNY

Over the twelve months ended September 30, 2026, SMO ClinPlus Co., Ltd. Class A generated 819.71M in revenue and converted that into 29.65M in net income, yielding earnings per share of 0.37. EBITDA reached 43.67M, while operating income came in at 43.72M.

Revenue819.71M
Gross Profit134.71M
Operating Income43.72M
Pretax Income42.36M
Net Income29.65M
EBITDA43.67M
EBIT43.67M
Earnings Per Share (EPS)0.37

Balance Sheet

CNY

As of September 30, 2026, SMO ClinPlus Co., Ltd. Class A holds 550.27M in cash and equivalents against 2.17M in total debt, resulting in a net debt position of -214.66M. Total book value stands at 1.27B, with working capital of 956.43M providing operational flexibility.

Cash & Cash Equivalents550.27M
Total Debt2.17M
Net Debt-214.66M
Equity (Book Value)1.27B
Book Value Per Share16.08
Working Capital956.43M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-15.83M

Margins

Over the twelve months ended September 30, 2026, SMO ClinPlus Co., Ltd. Class A posted a gross margin of 16.43, reflecting its pricing power and cost economics. The operating margin of 5.33 and net profit margin of 3.62 provide insight into operational efficiency.

Gross Margin16.43
Operating Margin5.33
Pretax Margin5.17
Profit Margin3.62
EBITDA Margin5.33

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, SMO ClinPlus Co., Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of 18.12 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.39, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SMO ClinPlus Co., Ltd. Class A shareholders.

Dividend Per Share0.07
Payout Ratio18.12
Shareholder Yield1.39

Stock Splits

SMO ClinPlus Co., Ltd. Class A's most recent stock split took place on June 6, 2024 with a 10:13 split ratio.

Last Split Date6/6/2024
Split Ratio10:13

Scores

As of September 30, 2026, SMO ClinPlus Co., Ltd. Class A has an Altman Z-Score of 10.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score10.01